Are lower MRPs on cancer drugs translating into affordable care?
Summary
- The National Pharmaceutical Pricing Authority (NPPA) imposed price caps on several high-cost oncology medicines in 2022.
- Since the caps, the Maximum Retail Prices (MRPs) of flagship cancer drugs such as imatinib and trastuzumab fell by 15-30 percent.
- Despite lower MRPs, out-of-pocket spending on cancer treatment remains above 25% of average household income due to ancillary costs like diagnostics and hospital charges.
- Only about 12% of diagnosed cancer patients in India currently have access to fully affordable treatment under existing price‑control mechanisms.
- Increased generic entry after patent expiries is gradually improving drug availability, but supply chain bottlenecks limit the impact.
Key Facts
- · NPPA introduced price caps on 27 oncology drugs in 2022.
- · Imatinib's MRP fell from INR 6,500 to INR 4,550 per month.
- · Trastuzumab's MRP fell from INR 45,000 to INR 32,000 per cycle.
- · Out-of-pocket cancer expenditure averages 27% of total household consumption expenditure.
- · Only 12% of cancer patients receive treatment deemed affordable (cost ≤10% of annual household income).
- · Generic versions of 9 capped drugs entered the market between 2022‑2024.
- · Diagnostic and hospitalization costs account for roughly 40% of total cancer care expenses.
- · The Ministry of Health plans a dedicated cancer insurance scheme by 2025 to bridge the affordability gap.
Why it matters
High drug prices impede universal health coverage and increase the financial burden on families, undermining India's commitment to equitable healthcare and affecting macroeconomic indicators such as household savings and poverty rates.
#cancer#drug pricing#MRP#affordable healthcare#government policy#pharmaceuticals